Clinical Studies: 2002 Start Date

Psoriasis
Sponsor: Genentech, Inc.
An Open—Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered XXXXX in Adults with Plaque Psoriasis Previously Enrolled in Study ACD2600g.
September 2002 to March 2004

Psoriasis
Sponsor: Genentech, Inc.
A Phase IIIB, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered XXXXX in Adults with Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy.
September 2002 to January 2003

Clinical Studies